CXCL9 and breast cancer: also suggested that the high expression levels of T‐cell‐related markers CD3D and CXCL9 caused a significantly increased pathologic complete response rate (pCR) in 1,058 pretherapeutic BC tissues from two neoadjuvant anthracycline/taxane‐based studies 43.